AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement

AELIX Therapeutics, a Metrix Partners client, and Gilead Sciences signed a clinical research collaboration agreement in October 2018. The partners agreed to evaluate a combination of AELIX’s HTI therapeutic vaccine and Gilead’s Toll-like receptor 7 (TLR7) agonist vesatolimod as a potential path to an HIV cure.

AELIX Therapeutics and Gilead Sciences collaboration

The collaboration

The agreement enabled a clinical study called AELIX-003. It tested the safety, tolerability, immunogenicity and efficacy of the combined regimen in people living with HIV who were on antiretroviral therapy, according to the AELIX announcement. The study was registered on ClinicalTrials.gov.

The scientific idea is to combine two mechanisms. The HTI vaccine trains T cells to recognise parts of HIV that are linked to natural control of the virus. Vesatolimod activates the innate immune system and may help expose the reservoir of virus that persists despite treatment. Together, they aim to let patients control HIV without daily medication.

About AELIX Therapeutics

AELIX is a Barcelona company that develops immunotherapies for HIV. Its HTI immunogen was designed by Dr Christian Brander and colleagues at IrsiCaixa. The company had started its first Phase I trial in 2017.

What came next

The partnership continued over several years. In November 2024, Gilead Sciences agreed to acquire AELIX’s HTI therapeutic HIV vaccine assets, after the vaccines showed promising results in Phase 1 and Phase 2 trials, as described in a press release published by Ysios Capital.

Five lessons on partnering with big pharma

  1. Start with a collaboration. A clinical collaboration lets both sides test fit before larger commitments.
  2. Combination trials create value. Testing a small company’s asset with a large partner’s drug can strengthen both.
  3. Negotiate data and IP rights. Who owns results, and who can use them, shapes future deals.
  4. Collaborations can lead to acquisitions. A working relationship gives the partner insight that supports a later purchase.
  5. Account for in-kind contributions. Drug supply and trial support from a partner need clear accounting and reporting.

What biotech founders should prepare for partnering

  • A clear data package for each asset.
  • IP ownership and licences documented.
  • A budget for the company’s share of joint trials.
  • Accounts reconciled to the statutory filings, with programme costs separated.
  • A view on deal structures and their accounting treatment.

Why Gilead Sciences partners with small biotechs

Gilead Sciences is one of the leading companies in HIV treatment and has a long-term programme of research toward a cure. No single company has all the scientific tools needed for that goal. Collaborations with smaller biotechs give Gilead Sciences access to new approaches, such as AELIX’s T-cell vaccine, without acquiring the whole company at an early stage. For the smaller partner, the collaboration brings clinical supply, scientific input and validation from a market leader.

This model has become common in infectious disease and oncology. It also creates a natural route to a later acquisition when the data supports it, as happened with AELIX.

Metrix Partners in life sciences

Metrix supports life sciences clients through financing, partnering and exits. Other examples include the sale of MSC-1 to AstraZeneca, Boehringer Ingelheim’s acquisition of Northern Biologics and Ona Therapeutics’ Series A.